替加环素辅助治疗老年MDRAB肺炎患者的疗效  

Clinical efficacy of tigecycline in the adjuvant treatment of elderly patients with MDRAB pneumonia

作　　者：张洁[1] 陈苗[1] 崔婷婷[1] ZHANG Jie;CHEN Miao;CUI Tingting(Jiaozuo People's Hospital,Jiaozuo 454000,Henan)

机构地区：[1]焦作市人民医院,河南焦作454000

出　　处：《菏泽医学专科学校学报》2021年第4期13-16,共4页Journal of Heze Medical College

摘　　要：目的探讨老年多重耐药鲍氏不动杆菌(MDRAB)肺炎患者采用替加环素辅助治疗的临床效果。方法选取老年MDRAB肺炎患者127例,采用抽签法将患者分为两组,对照组接受头孢哌酮舒巴坦钠治疗,观察组在对照组基础上接受替加环素静脉滴注治疗,对比两组的临床疗效以及细菌清除率、炎症指标水平、病情恶化程度、血TLR-4、Ⅳ-C及MMP-9水平、不良反应。结果治疗后观察组的临床疗效、细菌清除率均高于对照组(P<0.05);炎症指标结果显示,对照组治疗后PCT、WBC、CRP水平均低于治疗前,且观察组炎症指标水平明显低于对照组(P<0.05);两组治疗后的病情恶化程度评分均低于治疗前,且观察组低于对照组(P<0.05);治疗后对照组血Ⅳ-C、MMP-9、TLR-4水平明显高于观察组(P<0.05);两组不良反应发生率比较,P>0.05。结论老年MDRAB肺炎患者采用替加环素辅助治疗,可有效改善患者的临床症状,降低患者的炎症因子水平,同时具有较高的药物安全性。Objective To explore the clinical effect of tigecycline in the adjuvant treatment of elderly patients with multidrug-resistant acinetobacter baumannii(MDRAB) pneumonia. Methods 127 elderly patients with multidrug-resistant MDRAB pneumonia were selected and randomly divided into two groups. The control group received cefoperazone sulbactam sodium treatment, and the observation group received tigecycline intravenously on the basis of the control group.The clinical efficacy, bacterial clearance rate, inflammatory index level, disease deterioration degree, the levels of TLR-4,Ⅳ-C and MMP-9, and adverse reactions were compared between the two groups. Results The clinical efficacy and bacterial clearance rate of the observation group were higher than those of the control group(P<0.05). The inflammation index results showed that the PCT, WBC and CRP levels after treatment in the control group were lower than those before treatment, and the inflammatory indexes in the observation group were significantly lower than those of the control group(P<0.05). The scores of disease deterioration degree in the two groups after treatment were lower than those before treatment,and the observation group was lower than the control group(P<0.05). The levels of Ⅳ-C, MMP-9 and TLR-4 were significantly higher than those in the observation group(P<0.05). There was not statistically significant in the incidence of adverse reactions between the two groups(P>0.05). Conclusion The tigecycline can effectively improve the patient’s clinical symptoms, reduce the inflammatory factors with high drug safety in the treatment of elderly patients with MDRAB pneumonia.

关 键 词：替加环素 老年 多重耐药鲍氏不动杆菌 肺炎 炎症水平 

分 类 号：R563.1[医药卫生—呼吸系统]